Theradiag SA
PAR:ALTER
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Theradiag SA
Other Equity
Theradiag SA
Other Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Theradiag SA
PAR:ALTER
|
Other Equity
€1.1m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Edap Tms SA
NASDAQ:EDAP
|
Other Equity
€23.3m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
Biomerieux SA
PAR:BIM
|
Other Equity
-€234m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
Diagnostic Medical Systems SA
PAR:ALDMS
|
Other Equity
€1k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
SMAIO SA
PAR:ALSMA
|
Other Equity
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amplitude Surgical SA
PAR:AMPLI
|
Other Equity
-€664k
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
Theradiag SA
Glance View
Theradiag SA engages in the distribution, development and manufacturing of in vitro diagnostic and theranostics tests. The company is headquartered in Croissy-Beaubourg, Ile-De-France. The company went IPO on 2012-12-11. The firm develops and offers product panels for diagnosing autoimmune diseases, allergies, and infectious diseases. TheraDiags product offering consists of tests using a range of techniques (Elisa, rapid tests, immunofluorescence, Dot, immunochemical tests, molecular biology, etc.) as well as a range of automatic devices and solutions for high-speed diagnostics based on Luminexs Multiplex technology. The company has also developed a range of theranostic diagnostics commercialized under the Lisa-Tracker brand which provide monitoring of patients treated by anti-TNF monoclonal antibodies. TheraDiag is active in more than 30 countries, as an independent distributor.
See Also
What is Theradiag SA's Other Equity?
Other Equity
1.1m
EUR
Based on the financial report for Jun 30, 2023, Theradiag SA's Other Equity amounts to 1.1m EUR.
What is Theradiag SA's Other Equity growth rate?
Other Equity CAGR 5Y
-5%
Over the last year, the Other Equity growth was -3%. The average annual Other Equity growth rates for Theradiag SA have been 7% over the past three years , -5% over the past five years .
